Krebs Biochemicals Reports Q3FY26 Loss of ₹312.65 Lacs

Krebs Biochemicals & Industries posted a net loss of ₹312.65 lacs for Q3FY26, with revenue declining 36.55% YoY to ₹727.42 lacs. Manufacturing operations remain closed due to pollution board orders.

Krebs Biochemicals Reports Loss of Rs 1,146.73 Lacs for Half-Year Ended September 2025

Krebs Biochemicals Industries Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025. The company reported a loss before tax of Rs 1,146.73 lacs for the half-year period, compared to a loss of Rs 2,093.20 lacs in the corresponding period last year. Revenue from operations stood at Rs 1,977.70 lacs for the half-year. The company's cash and cash equivalents decreased to Rs 12.71 lacs as of September 30, 2025, from Rs 14.16 lacs at the beginning of the year. Net cash flow from operating activities was negative at Rs 167.56 lacs. The Board of Directors approved these results in a meeting held on November 4, 2025. The company operates in a single business segment and has no subsidiaries, associates, or joint venture companies.

Krebs Biochemicals Reports Rs 532.43 Lakh Loss for Quarter Ended June 30, 2025

Krebs Biochemicals and Industries Limited published its unaudited financial results for the quarter ended June 30, 2025. The company reported total income from operations of Rs 549.26 lakhs, down from Rs 643.85 lakhs in the previous quarter and Rs 1,292.25 lakhs in the same quarter last year. The company posted a net loss of Rs 532.43 lakhs for the quarter, compared to a loss of Rs 825.31 lakhs in the previous quarter and Rs 517.11 lakhs in the corresponding quarter of the previous year. Total comprehensive income showed a loss of Rs 532.43 lakhs. The company's equity share capital remained unchanged at Rs 2,156.06 lakhs. Basic and diluted earnings per share were negative at Rs 2.47 per share of Rs 10 each. The board approved these results on August 7, 2025, and they were published in newspapers on August 8, 2025.

Krebs Biochemicals Appoints New Managing Director & CEO, Announces Q1 Results

Krebs Biochemicals & Industries Ltd approved its unaudited financial results for the first quarter ended June 30, 2025. The company appointed Manish Kumar Jain as Additional Director and Managing Director & CEO effective August 7, 2025, for a five-year term until August 6, 2028, subject to shareholder approval. Jain is a Chartered Accountant with over 25 years of experience in Strategic Planning, Finance and Business Development. Simultaneously, Jitendra Shah resigned from his position as Managing Director & CEO effective August 7, 2025, citing personal reasons. The Board reconstituted its Audit Committee and Stakeholder Relationship Committee effective August 8, 2025, with both committees now including the new Managing Director alongside existing independent directors.